ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.
Synonyms: CDK4I; Cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; MTS-1; Multiple tumor suppressor 1; p16-INK4; p16INK4A
Storage: 2-8C
Application: Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected p16-INK4a in HeLa, A431, HUVEC, and NIH3T3 cells.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected p16-INK4a in human cervical cancer tissue sections.Affinity Binding Assay: A representative lot of this antibody bound recombinant p16-INK4a protein with a KD of 4.5 x 10-7 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany